A phase I/II trial of irinotecan–cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer

We conducted a phase I/II study in patients with advanced non-small-cell lung cancer (NSCLC) to increase the therapeutic index of the cisplatin–irinotecan combination by institution of an anti-late-diarrhoeal program (ADP). A total of 77 chemotherapy-naive patients with advanced NSCLC were enrolled....

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Takeda, Y, Tsuduki, E, Izumi, S, Hojo, M, Kamimura, M, Naka, G, Kobayashi, K, Kudo, K
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2005
Teme:
Clinical Study
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361534/
https://ncbi.nlm.nih.gov/pubmed/16288302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602866
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki